Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
May 01, 2026
Trimble Inc. (TRMB): AI Integrations Driving +14% YTD Gains and Analyst Optimism

Trimble Inc. (TRMB): AI Integrations Driving +14% YTD Gains and Analyst Optimism

Key Takeaways

  • Trimble's recent AI advancements, including SketchUp's Claude integration and Document Crunch acquisition, position it strongly in construction software.
  • Stock has gained over 14% year-to-date, trading around recent highs amid positive analyst reaffirmations.
  • Annualized recurring revenue (ARR) reached $2.39 billion, underscoring subscription model strength.
  • Analysts maintain Buy ratings with average price targets near $90-93.
  • Upcoming Q1 2026 earnings on May 6 expected to provide further guidance on AI-driven growth.

Current Market Snapshot

I've been keeping an eye on TRMB, and the stock has shown real resilience lately amid broader market swings. What stands out is how it's benefiting from AI-enhanced solutions tailored for construction and infrastructure. Shares have pushed higher in recent sessions, fueled by investor confidence in strategic AI moves and a strong recurring revenue foundation. Trading near recent highs within its 52-week range, TRMB has upside potential if catalysts keep coming, though it's not immune to headwinds like uncertainty in construction spending. From what I see, this steady performance, backed by software innovation and analyst backing, makes it worth watching for investors focused on precision technology.

Recent Developments Driving TRMB Price Action

In the last 30 days, TRMB has seen some targeted gains tied directly to AI-focused announcements, lifting sentiment around its construction and infrastructure software. On April 2, Trimble revealed plans to acquire Document Crunch, an AI platform for contract analysis and risk management in construction. This bolsters Trimble's automation of legal reviews, cuts disputes, and speeds up project workflows—key in an industry grappling with labor shortages and cost pressures. The news added to the positive momentum, aligning with Trimble's generative AI push for efficiency, which analysts like those at KeyBanc called "stronger than expected."

On April 29, Trimble brought Anthropic's Claude AI into its SketchUp 3D modeling software, adding conversational features for easier design and collaboration. Users can now query models in natural language, smoothing out architecture and engineering tasks. This sparked quick interest, with shares ticking up amid AI hype—lagging the S&P 500 a bit but beating some industrial peers. Reinforcing that were analyst updates: J.P. Morgan stuck with its Buy rating on April 10, and KeyBanc on April 9, highlighting solid ARR growth and AI support, even after Baird trimmed its target to $85 from $90 back in February.

Building on FY2025 results from February—$3.59 billion in revenue (organic growth) and $2.39 billion ARR—the spotlight is now on Q1 2026 earnings due May 6, with estimates at $906 million revenue and $0.71 EPS. Steady infrastructure spending and construction tech uptake have helped stability, though shares hit toward 52-week lows earlier in April before rebounding on AI updates. These moves have lifted shares 1.5-3% in spots, with AI clearly driving sentiment in a mixed sector. I also checked recent patterns using Tickeron’s AI Real Time Patterns tool, which confirmed the bullish shift.

Tools I'm Watching: Tickeron’s Trending AI Robots

In my own research and trading setup, I regularly turn to Tickeron’s Trending AI Robots page for insights into top performers. It spotlights the platform's leading 25 AI trading bots out of more than 350 that cover thousands of tickers in stocks, ETFs, and crypto. Powered by advanced AI and machine learning, they deliver real-time signals across strategies like trend following, swing trading, multi-agent portfolios, and technical or fundamental analysis—from 5-minute to 50-day frames. Standouts show annualized returns of +24% to +165%, win rates from 51% to 88%, and profit factors up to 11.7, spanning sectors like semiconductors (NVDA, AMD), industrials, small caps, and leveraged ETFs. With options for signal, virtual, or brokerage agents to match different risk levels and volatility, they’ve become a practical addition to my toolkit.

2026 Outlook and Key Factors to Monitor

Looking ahead to 2026, Trimble's guidance calls for $3.81-3.91 billion in revenue and GAAP EPS of $2.04-2.23, driven by organic growth in recurring software and AI upgrades. One thing I'm tracking closely is ARR growth past $2.39 billion, as it delivers reliable high-margin revenue against cyclical construction demand. Opportunities lie in deeper AI adoption, like Claude in SketchUp and synergies from Document Crunch, which could grab more share in digital workflows. Trends like labor shortages (from Trimble's contractor survey) and BIM adoption play right into its positioning tech.

On the flip side, watch for macro hits to infrastructure capex, supply chain issues, and rivals like Autodesk or Hexagon. Data privacy regs for AI and execution on small acquisitions matter too. Consensus analyst targets sit at $92-93 on average, suggesting upside, but Q1 results, releases like Tekla 2026, and 4-6% organic growth targets will be pivotal. In my view, Trimble's emphasis on AI agents and programmable ecosystems sets it up well for smart infrastructure long-term. To compare peers, I ran a quick check with Tickeron’s AI Screener.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: TRMB

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


TRMB in downward trend: 10-day moving average moved below 50-day moving average on September 30, 2026

The 10-day moving average for TRMB crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 54 cases where TRMB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for TRMB turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

The Aroon Indicator for TRMB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on TRMB as a result. In 55 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

TRMB moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRMB advanced for three days, in 197 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

TRMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.624) is normal, around the industry mean (4.255). P/E Ratio (30.665) is within average values for comparable stocks, (88.653). Projected Growth (PEG Ratio) (1.355) is also within normal values, averaging (5.470). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (3.589) is also within normal values, averaging (32.028).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. TRMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 9.16B. The market cap for tickers in the group ranges from 12.56K to 120.89B. KYCCF holds the highest valuation in this group at 120.89B. The lowest valued company is FLXT at 12.56K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -2%. SOTK experienced the highest price growth at 34%, while SVRE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 57
Price Growth Rating: 55
SMR Rating: 78
Profit Risk Rating: 80
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
TRMB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a devloper of advanced positioning product solutions

Industry ElectronicEquipmentInstruments

Industry
Telecommunications Equipment
Address
10368 Westmoor Drive
Phone
+1 720 887-6100
Employees
11500
Web
https://www.trimble.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.